Read an important notice regarding the data security incident McKesson reported on August 28, 2026. Read more.
USOR 24246 - Ph2 Study of Fruquintinib plus FOLFIRI as 2L Treatment for mCRC
A Phase II Study Investigating Fruquintinib plus FOLFIRI as Second-Line Treatment for Participants with Metastatic Colorectal Cancer (FRUITFUL)
Disease Types: Colorectal
Available at: Arlington Heights, Niles, Chicago